Baricitinib and dexamethasone for hospitalized patients with COVID-19

Link to article at PubMed

Cleve Clin J Med. 2021 Feb 1. doi: 10.3949/ccjm.88a.ccc073. Online ahead of print.


The glucocorticoid dexamethasone is the standard of care in critically ill patients with COVID-19 to suppress the inappropriately heightened inflammatory response (cytokine storm), but the Janus kinase inhibitor baricitinib combined with remdesivir has received emergency use authorization for the same indication. As of this writing, in a hospitalized patient with COVID-19 who has evidence of pneumonitis or hypoxia, we recommend using either regimen, but not both together. Both regimens have shown benefit in randomized controlled trials, but we cannot state with certainty that either is superior to the other, nor whether they should be used together. Further trials are underway.

PMID:33526440 | DOI:10.3949/ccjm.88a.ccc073

Leave a Reply

Your email address will not be published. Required fields are marked *